1
|
Altwal J, Lee BI, Boss MK, LaRue SM, Martin TW. Outcomes of 35 dogs with craniomaxillofacial osteosarcoma treated with stereotactic body radiation therapy. Vet Comp Oncol 2024; 22:125-135. [PMID: 38246695 DOI: 10.1111/vco.12960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Revised: 12/19/2023] [Accepted: 12/21/2023] [Indexed: 01/23/2024]
Abstract
Canine craniomaxillofacial osteosarcoma (OSA) is most commonly treated surgically; however, in cases where surgery is not feasible or non-invasive treatment is desired, stereotactic body radiation therapy (SBRT) may be elected for local tumour control. In this study, we evaluated 35 dogs treated with SBRT. Nine dogs (26%) had calvarial, seven (20%) had mandibular and 19 (54%) had maxillary OSA. Median time to first event (TFE) was 171 days, and overall median survival time (MST) was 232 days. Site-specific MSTs were 144 days for mandible, 236 days for calvarium and 232 days for maxilla (p = .49). Pulmonary metastatic disease was observed in 12/35 (34%) patients and was detected pre-SBRT in six dogs (17%) and post-SBRT in the remaining six dogs (17%). Eighteen adverse events post-SBRT were documented. Per veterinary radiation therapy oncology group criteria, five were acute (14%) and three were late (9%) grade 3 events. Neurological signs in two dogs were suspected to be early-delayed effects. Cause of death was local progression for 22/35 (63%) patients, metastasis for 9/35 (26%) patients and unknown for four. On univariate analysis, administration of chemotherapy was associated with a longer TFE (p = .0163), whereas volume of gross tumour volume was associated with a shorter TFE (p = .023). Administration of chemotherapy and five fractions versus single fraction of SBRT was associated with increased survival time (p = .0021 and .049). Based on these findings, a treatment protocol incorporating chemotherapy and five fractions of SBRT could be considered for dogs with craniomaxillofacial OSA electing SBRT with careful consideration of normal tissues in the field.
Collapse
Affiliation(s)
- Johnny Altwal
- College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA
| | - Ber-In Lee
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA
| | - Mary-Keara Boss
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA
| | - Susan M LaRue
- Department of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA
| | - Tiffany Wormhoudt Martin
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA
| |
Collapse
|
2
|
Rafalko JM, Kruglyak KM, McCleary-Wheeler AL, Goyal V, Phelps-Dunn A, Wong LK, Warren CD, Brandstetter G, Rosentel MC, DiMarzio L, McLennan LM, O’Kell AL, Cohen TA, Grosu DS, Chibuk J, Tsui DWY, Chorny I, Flory A. Age at cancer diagnosis by breed, weight, sex, and cancer type in a cohort of more than 3,000 dogs: Determining the optimal age to initiate cancer screening in canine patients. PLoS One 2023; 18:e0280795. [PMID: 36724177 PMCID: PMC9891508 DOI: 10.1371/journal.pone.0280795] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2022] [Accepted: 01/09/2023] [Indexed: 02/02/2023] Open
Abstract
The goal of cancer screening is to detect disease at an early stage when treatment may be more effective. Cancer screening in dogs has relied upon annual physical examinations and routine laboratory tests, which are largely inadequate for detecting preclinical disease. With the introduction of non-invasive liquid biopsy cancer detection methods, the discussion is shifting from how to screen dogs for cancer to when to screen dogs for cancer. To address this question, we analyzed data from 3,452 cancer-diagnosed dogs to determine the age at which dogs of certain breeds and weights are typically diagnosed with cancer. In our study population, the median age at cancer diagnosis was 8.8 years, with males diagnosed at younger ages than females, and neutered dogs diagnosed at significantly later ages than intact dogs. Overall, weight was inversely correlated with age at cancer diagnosis, and purebred dogs were diagnosed at significantly younger ages than mixed-breed dogs. For breeds represented by ≥10 dogs, a breed-based median age at diagnosis was calculated. A weight-based linear regression model was developed to predict the median age at diagnosis for breeds represented by ≤10 dogs and for mixed-breed dogs. Our findings, combined with findings from previous studies which established a long duration of the preclinical phase of cancer development in dogs, suggest that it might be reasonable to consider annual cancer screening starting 2 years prior to the median age at cancer diagnosis for dogs of similar breed or weight. This logic would support a general recommendation to start cancer screening for all dogs at the age of 7, and as early as age 4 for breeds with a lower median age at cancer diagnosis, in order to increase the likelihood of early detection and treatment.
Collapse
Affiliation(s)
- Jill M. Rafalko
- Medical & Clinical Affairs, PetDx, La Jolla, California, United States of America
- * E-mail:
| | - Kristina M. Kruglyak
- Information Technology & Bioinformatics, PetDx, La Jolla, California, United States of America
| | | | - Vidit Goyal
- Information Technology & Bioinformatics, PetDx, La Jolla, California, United States of America
| | - Ashley Phelps-Dunn
- Medical & Clinical Affairs, PetDx, La Jolla, California, United States of America
| | - Lilian K. Wong
- Medical & Clinical Affairs, PetDx, La Jolla, California, United States of America
| | - Chelsea D. Warren
- Medical & Clinical Affairs, PetDx, La Jolla, California, United States of America
| | - Gina Brandstetter
- Medical & Clinical Affairs, PetDx, La Jolla, California, United States of America
| | - Michelle C. Rosentel
- Medical & Clinical Affairs, PetDx, La Jolla, California, United States of America
| | - Lauren DiMarzio
- Medical & Clinical Affairs, PetDx, La Jolla, California, United States of America
| | - Lisa M. McLennan
- Clinical Studies, PetDx, La Jolla, California, United States of America
| | - Allison L. O’Kell
- Medical & Clinical Affairs, PetDx, La Jolla, California, United States of America
| | - Todd A. Cohen
- Medical & Clinical Affairs, PetDx, La Jolla, California, United States of America
| | - Daniel S. Grosu
- Chief Executive Officer, PetDx, La Jolla, California, United States of America
| | - Jason Chibuk
- Medical & Clinical Affairs, PetDx, La Jolla, California, United States of America
| | - Dana W. Y. Tsui
- Research & Development, PetDx, La Jolla, California, United States of America
| | - Ilya Chorny
- Information Technology & Bioinformatics, PetDx, La Jolla, California, United States of America
| | - Andi Flory
- Medical & Clinical Affairs, PetDx, La Jolla, California, United States of America
| |
Collapse
|
3
|
Musharbash FN, Edelstein A, El Abiad JM, Levin AS, Alcorn SR, Morris CD. Risk of Malignant Transformation of Giant Cell Tumors of Bone Is 8 Times Lower with Megavoltage vs. Orthovoltage Radiation Therapy. Sarcoma 2022; 2022:7216296. [PMID: 36311815 PMCID: PMC9616653 DOI: 10.1155/2022/7216296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Revised: 08/12/2022] [Accepted: 09/28/2022] [Indexed: 11/17/2022] Open
Abstract
Background The first-line treatment for most giant cell tumors (GCTs) of bone is surgical; radiotherapy (RT) is reserved for inoperable or refractory cases. While RT techniques have undergone a dramatic change over the past few decades, with the higher energy megavoltage RT replacing orthovoltage RT, concerns for high rates of malignant transformation following RT have limited its use. Evidence suggests a lower incidence of secondary malignancy after treatment with megavoltage compared with orthovoltage RT, but this has not been studied in GCTs. Our main purpose was to compare the incidence of malignant transformation of GCTB between patients treated with orthovoltage vs. megavoltage RT. Methods A literature review was performed to identify studies reporting GCTBs treated with RT from 01/1900 through 12/2019. Studies that did not report RT modality or separate orthovoltage and megavoltage results were excluded. Included in the analysis were 6 patients from our institution. Primary outcome was the incidence of malignant transformation; secondary outcomes were time to transformation and incidence of local recurrence. Fisher's exact tests and independent sample t-tests were used, and significance was set at p < 0.05. Results Twenty-two studies were included, which reported on 168 GCTBs treated with orthovoltage and 393 treated with megavoltage RT. Transformation incidence was 14% (n = 24) for orthovoltage and 1.8% (n = 7) for megavoltage RT, an 8-fold difference (odds ratio (OR) 9.1, 95% confidence interval (CI) 3.9-22, p < 0.001). Mean time to transformation was 8.7 years for orthovoltage and 11.2 years for megavoltage RT (p=0.28). Incidence of local recurrence was 38% (63/167) for orthovoltage and 17% (66/393) for megavoltage RT (OR 3.3, 95% CI 2.0-4.6, p < 0.001). Conclusions The risk of developing a malignancy after RT of GCTB is 8 times lower with megavoltage than with orthovoltage. Malignant transformation with megavoltage, while not zero, is lower than that in historical series. Use of modern RT techniques in inoperable or refractory GCTB may be appropriate.
Collapse
Affiliation(s)
- Farah N. Musharbash
- Department of Orthopaedic Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Alexander Edelstein
- Department of Orthopaedic Surgery, Guthrie Robert Packer Hospital, Sayre, Pennsylvania, USA
| | - Jad M. El Abiad
- Department of Orthopaedic Surgery, American University of Beirut, Beirut, Lebanon
| | - Adam S. Levin
- Department of Orthopaedic Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Sara R. Alcorn
- Department of Radiation Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Carol D. Morris
- Department of Orthopaedic Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| |
Collapse
|
4
|
Jimenez IA, Pool RR, Gabrielson KL. Canine Idiopathic Arteriopathy, Appendicular Bone Infarcts, and Neoplastic Transformation of Bone Infarcts in 108 Dogs ( Canis lupus familiaris). Comp Med 2022; 72:306-319. [PMID: 36113969 PMCID: PMC9827601 DOI: 10.30802/aalas-cm-22-000037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2022] [Revised: 05/27/2022] [Accepted: 07/26/2022] [Indexed: 01/27/2023]
Abstract
Osteosarcoma (OSA) is the most common primary bone tumor in both dogs and humans. The dog is an important research model for OSA, yet dogs have much higher prevalence of bone tumors than do humans, a disparity that has yet to be explained. Neoplastic transformation of cells within or adjacent to bone infarcts into primary bone tumors has been described in humans but only sparsely characterized in the veterinary literature. In this study, 653 cases of canine bone infarcts were received through a referral veterinary osteopathology service over a 14-y period. We identified an idiopathic disorder affecting the nutrient artery, termed canine idiopathic arteriopathy (CIA), which to our knowledge has no direct counterpart in human medicine. This disorder was documented alongside ischemic necrosis of the medullary cavity in 114 bone infarcts in 108 dogs. We hypothesize that CIA precipitated an ischemic environment, resulting in development of a bone infarct down- stream of the abnormal artery. In 52% (59 of 114) of cases, bone infarcts demonstrated evidence of repair (termed reparative bone infarcts [RBI]), while in 48% (55 of 114) of infarcts, a bone tumor was also present, including pleomorphic sarcoma, OSA, fibrosarcoma, and chondrosarcoma. In some cases, a spectrum of tumors was present. We hypothesize that the ischemic infarct environment provoked bone marrow mesenchymal stem cells (MSCs) to attempt repair of the stroma, and in approximately half of cases, MSCs underwent neoplastic transformation (BINT) to produce tumors. The most common sites of bone infarcts were the distal femur, distal radius, proximal humerus, and distal tibia, coinciding with common sites of canine OSA. The authors propose that CIA leading to bone infarcts and infarct-derived tumors, in combination with possible underdiagnosis of canine bone infarcts and misdiagnosis of some RBI as neoplasia, may contribute to the higher reported proportion of bone tumors in dogs compared with humans.
Collapse
Affiliation(s)
- Isabel A Jimenez
- Department of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland;,
| | - Roy R Pool
- Department of Veterinary Pathobiology, Texas A&M College of Veterinary Medicine & Biomedical Sciences, College Station, Texas
| | - Kathleen L Gabrielson
- Department of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| |
Collapse
|
5
|
Shao R, Wang Y, Li L, Dong Y, Zhao J, Liang W. Bone tumors effective therapy through functionalized hydrogels: current developments and future expectations. Drug Deliv 2022; 29:1631-1647. [PMID: 35612368 PMCID: PMC9154780 DOI: 10.1080/10717544.2022.2075983] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Primary bone tumors especially, sarcomas affect adolescents the most because it originates from osteoblasts cells responsible for bone growth. Chemotherapy, surgery, and radiation therapy are the most often used clinical treatments. Regrettably, surgical resection frequently fails to entirely eradicate the tumor, which is the primary cause of metastasis and postoperative recurrence, leading to a high death rate. Additionally, bone tumors frequently penetrate significant regions of bone, rendering them incapable of self-repair, and impairing patients' quality of life. As a result, treating bone tumors and regenerating bone in the clinic is difficult. In recent decades, numerous sorts of alternative therapy approaches have been investigated due to a lack of approved treatments. Among the novel therapeutic approaches, hydrogel-based anticancer therapy has cleared the way for the development of new targeted techniques for treating bone cancer and bone regeneration. They include strategies such as co-delivery of several drug payloads, enhancing their biodistribution and transport capabilities, normalizing accumulation, and optimizing drug release profiles to decrease the limitations of current therapy. This review discusses current advances in functionalized hydrogels to develop a new technique for treating bone tumors by reducing postoperative tumor recurrence and promoting tissue repair.
Collapse
Affiliation(s)
- Ruyi Shao
- Department of Orthopedics, Zhuji People's Hospital, Shaoxing, Zhejiang, China
| | - Yeben Wang
- Department of Traumatic Orthopedics, Affiliated Jinan Third Hospital of Jining Medical University, Jinan, Shandong, China
| | - Laifeng Li
- Department of Traumatic Orthopedics, Affiliated Jinan Third Hospital of Jining Medical University, Jinan, Shandong, China
| | - Yongqiang Dong
- Department of Orthopaedics, Xinchang People's Hospital, Shaoxing, Zhejiang, China
| | - Jiayi Zhao
- Department of Orthopedics, Zhoushan Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Zhoushan, Zhejiang, China
| | - Wenqing Liang
- Department of Orthopedics, Zhoushan Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Zhoushan, Zhejiang, China
| |
Collapse
|
6
|
Jimenez IA, Pool RR, Fischetti AJ, Gabrielson K, Canapp SO. Neoplastic transformation of arteriopathy‐derived bone infarct into nascent osteosarcoma in the proximal tibia of a miniature schnauzer. VETERINARY RECORD CASE REPORTS 2022. [DOI: 10.1002/vrc2.293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Isabel A. Jimenez
- Veterinary Orthopedic and Sports Medicine Group Annapolis Junction Maryland USA
- Department of Molecular and Comparative Pathobiology The Johns Hopkins University School of Medicine Baltimore Maryland USA
| | - Roy R. Pool
- Department of Veterinary Pathobiology Texas A&M College of Veterinary Medicine & Biomedical Sciences College Station Texas USA
| | | | - Kathy Gabrielson
- Department of Molecular and Comparative Pathobiology The Johns Hopkins University School of Medicine Baltimore Maryland USA
| | - Sherman O. Canapp
- Veterinary Orthopedic and Sports Medicine Group Annapolis Junction Maryland USA
| |
Collapse
|
7
|
Gieger T, Haney S, Nolan MW. Re-irradiation of canine non-lymphomatous nasal tumors using stereotactic radiation therapy (10 Gy x 3) for both courses: assessment of outcome and toxicity in 11 dogs. Vet Comp Oncol 2022; 20:502-508. [PMID: 35023604 PMCID: PMC9305852 DOI: 10.1111/vco.12801] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 01/10/2022] [Accepted: 01/10/2022] [Indexed: 12/02/2022]
Abstract
No uniformly beneficial treatments exist for dogs with non‐lymphomatous nasal tumours (NLNT) that relapse after radiotherapy (RT). Reirradiation may prolong survival and improve quality of life. In this retrospective study, we describe outcomes for 11 dogs that had CT‐confirmed locoregional progression of NLNT after an initial course of stereotactic RT (SRT#1; 10 Gy × 3) and were then re‐treated with the same type of protocol (SRT#2, also 10 Gy × 3). The median time between SRT #1 and SRT #2 was 243 days (95% CI: 78–385 days). Ten dogs (91%) had a clinical benefit after SRT#1; five dogs (45%) had clinical benefit after SRT#2. Adverse events after SRT#2 included nasocutaneous or oronasal fistula formation (N = 3 at 180, 270, and 468 days), seizures (N = 2 at 78 and 330 days), bacterial or fungal rhinitis (N = 2 at 240 and 385 days), and facial swelling (N = 1 at 90 days). All 11 dogs have died, due to disease progression, presumed radiotoxicity, or declining quality of life; in most cases, it was difficult to discern between these conditions. The median overall survival time (OST) from SRT#1 was 745 days (95% CI: 360–1132). The median overall survival time (OST) from SRT #2 was 448 days (95% CI: 112–626). For these dogs, survival was prolonged, but adverse events after SRT#2 were common (8/11; 73%). Therefore, before consenting to re‐irradiation with this protocol, pet owners should be counselled about survivorship challenges, including risk for severe toxicities, and persistence of clinical signs.
Collapse
Affiliation(s)
- Tracy Gieger
- Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, United States.,Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina, United States
| | - Siobhan Haney
- Hope Veterinary Specialists and the Veterinary CyberKnife Cancer Center, Malvern, Pennsylvania, United States
| | - Michael W Nolan
- Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, United States.,Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina, United States.,Duke Cancer Institute, Duke University, Durham, North Carolina, United States
| |
Collapse
|
8
|
Swieton N, Nykamp SG, Poirier VJ, Wainberg S, Oblak ML. Suspected Radiation-Induced Osteosarcoma in a Domestic Shorthair Cat. Case Rep Vet Med 2020; 2020:1874342. [PMID: 31976121 PMCID: PMC6961608 DOI: 10.1155/2020/1874342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2019] [Accepted: 10/17/2019] [Indexed: 11/17/2022] Open
Abstract
A 3-year-old, male neutered domestic shorthair cat, presented for acute onset tail paresis. He was diagnosed with a spindle cell tumour at the level of L7-CD1 and treated with course fractionation radiation therapy. Three years following radiation therapy, the cat developed chondroblastic osteosarcoma of the pelvis, suspected to be secondary to radiation therapy. Hemipelvectomy was performed and the cat was treated with radiation therapy for remaining gross disease. The cat was euthanized 127 days post-operatively due to suspected metastatic disease. Development of radiation-induced tumours should be considered as a rare late complication in cats undergoing radiation therapy.
Collapse
Affiliation(s)
- Natalie Swieton
- Atlantic Veterinary College, University of Prince Edward Island, Charlottetown, PE, Canada C1A 4P3
| | - Stephanie G. Nykamp
- Ontario Veterinary College, University of Guelph, Guelph, ON, Canada N1G 2W1
| | - Valérie J. Poirier
- Ontario Veterinary College, University of Guelph, Guelph, ON, Canada N1G 2W1
| | - Shannon Wainberg
- Ontario Veterinary College, University of Guelph, Guelph, ON, Canada N1G 2W1
| | - Michelle L. Oblak
- Ontario Veterinary College, University of Guelph, Guelph, ON, Canada N1G 2W1
| |
Collapse
|
9
|
Callanan GF, Curran KM, Parachini-Winter C, Bracha S, Spagnoli S, Russell DS, Stieger-Vanegas SM, Griffin L, Leeper H. Nasal adenocarcinoma as a suspected secondary malignant neoplasm in a cat previously treated for nasal lymphoma. JFMS Open Rep 2020; 6:2055116920908351. [PMID: 32166040 PMCID: PMC7052471 DOI: 10.1177/2055116920908351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
CASE SUMMARY A case of nasal adenocarcinoma as a suspected secondary malignant neoplasm following definitive radiation therapy and multiagent chemotherapy for nasal lymphoma is described. An 11-year-old spayed female domestic shorthair cat was presented for a 3-week history of progressive facial swelling located over the nasal planum and extending to the medial canthus of the right eye. The cat was previously diagnosed with nasal lymphoma and treated with chemotherapy and definitive radiation 2.5 years prior. Although a definitive diagnosis could not be obtained via cytology, recurrent lymphoma was suspected based on the cat's history and recurrent clinical signs. A lymphoma-directed chemotherapy protocol was attempted, but no clinical response was achieved. The cat was euthanased owing to progressive clinical signs and a diagnosis of nasal adenocarcinoma was made on necropsy examination. Both the original diagnosis of nasal lymphoma and the secondary diagnosis of nasal adenocarcinoma were confirmed with immunohistochemistry. RELEVANCE AND NOVEL INFORMATION Secondary malignant neoplasm following radiation therapy is infrequently reported in the veterinary literature. In the few reports that exist, most have described sarcoma development in the dog following radiation therapy. In the present report, we describe a cat with a suspected radiation-induced nasal adenocarcinoma that developed 2.5 years after definitive radiation treatment for nasal lymphoma.
Collapse
Affiliation(s)
- Gabrielle F Callanan
- Department of Clinical Sciences, Carlson
College of Veterinary Medicine, Oregon State University, Corvallis, OR, USA
| | - Kaitlin M Curran
- Department of Clinical Sciences, Carlson
College of Veterinary Medicine, Oregon State University, Corvallis, OR, USA
| | - Cyril Parachini-Winter
- Department of Clinical Sciences, Carlson
College of Veterinary Medicine, Oregon State University, Corvallis, OR, USA
| | - Shay Bracha
- Department of Clinical Sciences, Carlson
College of Veterinary Medicine, Oregon State University, Corvallis, OR, USA
| | - Sean Spagnoli
- Department of Biomedical Sciences,
Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR,
USA
| | - Duncan S Russell
- Department of Biomedical Sciences,
Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR,
USA
| | - Susanne M Stieger-Vanegas
- Department of Clinical Sciences, Carlson
College of Veterinary Medicine, Oregon State University, Corvallis, OR, USA
| | - Lynn Griffin
- College of Veterinary Medicine and
Biomedical Sciences, Colorado State University, Fort Collins, CO, USA
| | - Haley Leeper
- Department of Clinical Sciences, Carlson
College of Veterinary Medicine, Oregon State University, Corvallis, OR, USA
| |
Collapse
|
10
|
Cook MR, Martinez MP, Fenger JM, Desai NC. Radiation-induced sarcoma in a cat following hypofractionated, palliative intent radiation therapy for large-cell lymphoma. JFMS Open Rep 2019; 5:2055116919889159. [PMID: 31819802 PMCID: PMC6882035 DOI: 10.1177/2055116919889159] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
CASE SUMMARY A 5-year-old female spayed domestic shorthair cat was presented with a 4.5 × 3 cm ulcerated cutaneous mass on the nasal bridge with extension into the nasal cavity. Tissue biopsy was obtained and a diagnosis of large-cell lymphoma was confirmed on histopathology. The cat was started on prednisolone and injectable chemotherapy; however, only a partial response was observed. A CT scan revealed a highly infiltrative mass with extensive subcutaneous involvement, extending into the nasal cavity, resulting in lysis of numerous nasal and facial bones. The cat received hypofractionated, palliative intent radiation therapy (four fractions of 8 Gray) and a complete clinical response was achieved. Nine months after radiation therapy, minimal residual intranasal disease was observed on advanced imaging. Sixty-nine months after the completion of radiotherapy, a mass was observed dorsal to the right eye within the previous radiation field. CT scan revealed a mass associated with the right frontal sinus with extension throughout the nasal cavity and facial bones. Histopathology was consistent with a moderately differentiated sarcoma. Seventy-one months post-radiation therapy, the cat developed neurologic clinical signs and was humanely euthanized. Radiation-induced sarcoma was suspected based on human criteria, which included history of irradiation and tumor development within the irradiated field, a latent period after irradiation prior to the development of the second tumor and histopathologic confirmation of a different malignant neoplasm at the irradiated site. RELEVANCE AND NOVEL INFORMATION To our knowledge, this is the first report of a malignant radiation-induced sarcoma in a cat. Based on this case, radiation-induced sarcomas should be considered as a late-term side effect associated with radiation therapy in cats.
Collapse
Affiliation(s)
- Matthew R Cook
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine at The Ohio State University, Columbus, OH, USA
| | - Michael P Martinez
- Department of Veterinary Biosciences at The Ohio State University, Columbus, OH, USA
| | - Joelle M Fenger
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine at The Ohio State University, Columbus, OH, USA
| | - Noopur C Desai
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine at The Ohio State University, Columbus, OH, USA
| |
Collapse
|
11
|
Wright KZ, Hohenhaus AE, Verrilli AM, Vaughan-Wasser S. Feline large-cell lymphoma following previous treatment for small-cell gastrointestinal lymphoma: incidence, clinical signs, clinicopathologic data, treatment of a secondary malignancy, response and survival. J Feline Med Surg 2019; 21:353-362. [PMID: 29877752 PMCID: PMC10814630 DOI: 10.1177/1098612x18779870] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVES Lymphoma is a common and clinically important malignancy in cats. Development of a second malignancy has been reported previously in 7-14% of cats with small-cell gastrointestinal (GI) lymphoma. The aim of our study was to describe the incidence, clinical signs, clinicopathologic data, response to therapy and outcomes in cats diagnosed with large-cell lymphoma following treatment for small-cell GI lymphoma. METHODS Medical records from a single referral specialty hospital were reviewed for all cats with lymphoma diagnosed between 2008 and 2017. The cases with a diagnosis of small-cell GI lymphoma followed by a diagnosis of any large-cell lymphoma and complete outcome data were selected for further review. RESULTS Seven hundred and forty cats with a diagnosis of lymphoma were identified. Twelve cats (12/121) treated for small-cell GI lymphoma followed by a diagnosis of any anatomic form of large cell lymphoma were identified. Nine cats met the study inclusion criteria and were used in analyses. Mean event-free survival time from small-cell GI lymphoma diagnosis until diagnosis of large-cell lymphoma was 543 days, with a median survival time of 615 days. Mean event-free survival time from large-cell lymphoma to death was 55 days, with a median survival time of 24.5 days. Hematocrit, albumin and total protein were significantly decreased when cats developed large-cell lymphoma compared with their values at the time of small-cell lymphoma diagnosis. CONCLUSIONS AND RELEVANCE Large-cell lymphoma occurred in 9.9% (12/121) of cats treated for small-cell GI lymphoma. Feline practitioners should include large-cell lymphoma on their list of differential diagnoses in cats diagnosed with small-cell GI lymphoma developing weight loss, anemia, hypoalbuminemia and hypoproteinemia.
Collapse
Affiliation(s)
- Katherine Z Wright
- The Cancer Institute, Animal Medical Center, New York, NY, USA
- Oncology Department, BluePearl Veterinary Partners, South Midvale, UT, USA
| | - Ann E Hohenhaus
- The Cancer Institute, Animal Medical Center, New York, NY, USA
| | | | | |
Collapse
|
12
|
Nagata K. A retrospective analysis of radiation oncology related scientific articles in the journal Veterinary Radiology and Ultrasound: Trends over 40 years (1976-2015). Vet Radiol Ultrasound 2019; 60:351-357. [PMID: 30776858 DOI: 10.1111/vru.12716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2018] [Revised: 11/19/2018] [Accepted: 11/26/2018] [Indexed: 11/29/2022] Open
Abstract
The journal Veterinary Radiology & Ultrasound is a veterinary specialty journal devoted to the fields of veterinary diagnostic imaging and radiation oncology. The purpose of this retrospective, observational study is to evaluate progressive trends in radiation oncology articles published in Veterinary Radiology & Ultrasound during the 40-year period (1976-2015) and describe a shift of trends through several viewpoints. This 40-year period was divided into four subperiods: Period 1 (1976-1985), Period 2 (1986-1995), Period 3 (1996-2005), and Period 4 (2006-2015). These articles were divided into six categories based on the nature of the study: 1) studies related to teletherapy with endpoints being patient outcome, 2) radiation therapy dosimetry/planning, 3) patient setup, 4) reviews, 5) case reports, and 6) others. The number of radiation oncology articles in Veterinary Radiology & Ultrasound has increased over the 40-year period. The number of authors per article has increased between Periods 1 and 3. The number of articles related to linear accelerator has increased between Periods 3 and 4. The median number of treated patients per clinical article related to teletherapy ranged from 15 to 21, which has not changed significantly over the 40-year period. The most commonly used radiation therapy protocols during Periods 2 and 3 were fine-fractionated protocols (defined as 10 or more fractions), whereas coarse-fractionated protocols were more common during Periods 1 and 4. Findings from this study highlight the notable changes of trends in veterinary radiation oncology articles published in Veterinary Radiology & Ultrasound, which clearly reflect changes in the field of veterinary radiation oncology during the past 40 years.
Collapse
Affiliation(s)
- Koichi Nagata
- College of Veterinary Medicine, Department of Veterinary Biosciences & Diagnostic Imaging, The University of Georgia, Athens, GA 30602
| |
Collapse
|
13
|
Wingo K. Histopathologic Diagnoses From Biopsies of the Oral Cavity in 403 Dogs and 73 Cats. J Vet Dent 2018; 35:7-17. [DOI: 10.1177/0898756418759760] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
This retrospective study documents the prevalence of various histopathological diagnoses within a practice specializing in veterinary dentistry and oral surgery. Histopathology results obtained from biopsies of oral lesions from 403 dogs and 73 cats were sorted and categorized. Lesions of inflammatory origin represented the most common histopathology result in cats (n = 37; 51%), followed by squamous cell carcinoma (n = 27; 37%). The most common histopathological diagnoses in dogs were malignant neoplasms (n = 151; 37%), followed by tumors of odontogenic origin (n = 138, 34%) and lesions of inflammatory origin (n = 114; 28%). The results of this study are representative of a private referral dentistry practice and are compared to other studies that assessed common oral neoplasia diagnoses in dogs and cats. Treatment options and prognoses of the most common canine and feline neoplasms are discussed.
Collapse
Affiliation(s)
- Kipp Wingo
- Arizona Veterinary Dental Specialists, Phoenix, AZ, USA
| |
Collapse
|
14
|
Bugueño J, Li W, Salat P, Qin L, Akintoye SO. The bone regenerative capacity of canine mesenchymal stem cells is regulated by site-specific multilineage differentiation. Oral Surg Oral Med Oral Pathol Oral Radiol 2016; 123:163-172. [PMID: 27876576 DOI: 10.1016/j.oooo.2016.09.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Revised: 08/08/2016] [Accepted: 09/14/2016] [Indexed: 12/19/2022]
Abstract
OBJECTIVES Mesenchymal stem cells (MSCs) offer a promising therapy in dentistry because of their multipotent properties. Selecting donor MSCs is crucial because Beagle dogs (canines) commonly used in preclinical studies have shown variable outcomes, and it is unclear whether canine MSCs (cMSCs) are skeletal site specific. This study tested whether jaw and long bone cMSCs have disparate in vitro and in vivo multilineage differentiation capabilities. STUDY DESIGN Primary cMSCs were isolated from the mandible (M-cMSCs) and femur (F-cMSCs) of four healthy Beagle dogs. The femur served as the non-oral control. Clonogenic and proliferative abilities were assessed. In vitro osteogenic, chondrogenic, adipogenic, and neural multilineage differentiation were correlated with in vivo bone regeneration and potential for clinical applications. RESULTS M-cMSCs displayed two-fold increase in clonogenic and proliferative capacities relative to F-cMSCs (P = .006). M-cMSCs in vitro osteogenesis based on alkaline phosphatase (P = .04), bone sialoprotein (P = .05), and osteocalcin (P = .03), as well as adipogenesis (P = .007) and chondrogenesis (P = .009), were relatively higher and correlated with enhanced M-cMSC bone regenerative capacity. Neural expression markers, nestin and βIII-tubulin, were not significantly different. CONCLUSIONS The enhanced differentiation and bone regenerative capacity of mandible MSCs may make them favorable donor graft materials for site-specific jaw bone regeneration.
Collapse
Affiliation(s)
- Juan Bugueño
- Department of Oral Medicine, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Weihua Li
- Department of Oral Medicine, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Pinky Salat
- Department of Oral Medicine, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Ling Qin
- Department of Orthopedics School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Sunday O Akintoye
- Department of Oral Medicine, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA.
| |
Collapse
|
15
|
Fan TM, Khanna C. Comparative Aspects of Osteosarcoma Pathogenesis in Humans and Dogs. Vet Sci 2015; 2:210-230. [PMID: 29061942 PMCID: PMC5644632 DOI: 10.3390/vetsci2030210] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2015] [Revised: 08/01/2015] [Accepted: 08/11/2015] [Indexed: 01/10/2023] Open
Abstract
Osteosarcoma (OS) is a primary and aggressive bone sarcoma affecting the skeleton of two principal species, human beings and canines. The biologic behavior of OS is conserved between people and dogs, and evidence suggests that fundamental discoveries in OS biology can be facilitated through detailed and comparative studies. In particular, the relative genetic homogeneity associated with specific dog breeds can provide opportunities to facilitate the discovery of key genetic drivers involved in OS pathogenesis, which, to-date, remain elusive. In this review, known causative factors that predispose to the development OS in human beings and dogs are summarized in detail. Based upon the commonalities shared in OS pathogenesis, it is likely that foundational discoveries in one species will be translationally relevant to the other and emphasizes the unique opportunities that might be gained through comparative scientific approaches.
Collapse
Affiliation(s)
- Timothy M Fan
- Department of Veterinary Clinical Medicine, Comparative Oncology Research Laboratory, University of Illinois at Urbana-Champaign, Urbana, IL 61820, USA.
| | - Chand Khanna
- Tumor and Metastasis Biology Section, Pediatric Oncology Branch, Center for Clinical Research, The National Cancer Institute, Washington, DC 20004, USA.
| |
Collapse
|
16
|
Nemec A, Arzi B, Hansen K, Murphy BG, Lommer MJ, Peralta S, Verstraete FJM. Osteonecrosis of the Jaws in Dogs in Previously Irradiated Fields: 13 Cases (1989-2014). Front Vet Sci 2015; 2:5. [PMID: 26664934 PMCID: PMC4672169 DOI: 10.3389/fvets.2015.00005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2015] [Accepted: 03/19/2015] [Indexed: 11/13/2022] Open
Abstract
The aim of this report was to characterize osteonecrosis of the jaws (ONJ) in previously irradiated fields in dogs that underwent radiotherapy (RT) for oral tumors. Osteoradionecrosis of the jaw (ORNJ) was further defined as osteonecrosis in a previously irradiated field in the absence of a tumor. Thirteen dogs clinically diagnosed with 15 ONJ lesions were included in this retrospective case series. Medical records were reviewed for: breed, sex, weight, and age of the patient, tumor type, location in the oral cavity and size, location of the ONJ, time from RT to ONJ onset, known duration of the ONJ, and tumor presence. Where available, histological assessment of tissues obtained from the primary tumor, and tissues obtained from the ONJ lesion, was performed, and computed tomographic (CT) images and dental radiographs were reviewed. RT and other treatment details were also reviewed. Twelve dogs developed ONJ in the area of the previously irradiated tumor or the jaw closest to the irradiated mucosal tumor. Recurrence of neoplasia was evident at the time of ONJ diagnosis in five dogs. Time from RT start to ONJ onset varied from 2 to 44 months. In three cases, ORNJ developed after dental extractions in the irradiated field. Dental radiographs mostly revealed a moth-eaten pattern of bone loss, CT mostly revealed osteolysis, and histopathology was consistent with osteonecrosis. To conclude, development of ONJ/ORNJ following RT is a rare, but potentially fatal complication. Patients undergoing RT may benefit from a comprehensive oral and dental examination and treatment prior to RT.
Collapse
Affiliation(s)
- Ana Nemec
- Clinic for Surgery and Small Animals, Veterinary Faculty, University of Ljubljana , Ljubljana , Slovenia ; Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California at Davis , Davis, CA , USA
| | - Boaz Arzi
- Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California at Davis , Davis, CA , USA
| | - Katherine Hansen
- Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California at Davis , Davis, CA , USA
| | - Brian G Murphy
- Department of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California at Davis , Davis, CA , USA
| | - Milinda J Lommer
- Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California at Davis , Davis, CA , USA ; Aggie Animal Dental Center , Mill Valley, CA , USA
| | - Santiago Peralta
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University , Ithaca, NY , USA
| | - Frank J M Verstraete
- Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California at Davis , Davis, CA , USA
| |
Collapse
|
17
|
Treggiari E, Ressel L, Polton GA, Benoit J, Desmas I, Blackwood L. Clinical outcome, PDGFRβ and KIT expression in feline histiocytic disorders: a multicentre study. Vet Comp Oncol 2015; 15:65-77. [PMID: 25665137 DOI: 10.1111/vco.12142] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2014] [Revised: 01/10/2015] [Accepted: 01/13/2015] [Indexed: 12/26/2022]
Abstract
Information about histiocytic disease in cats is limited. The aim of this study was to document clinical findings and outcome in feline histiocytic disorders, and characterize the expression of PDGFRβ and KIT in order to identify potential treatment targets. Morphologically diagnosed feline histiocytic tumours were reviewed and characterized by immunohistochemistry (IHC). Five cases of feline progressive histiocytosis (FPH), eight histiocytic sarcomas (HS) and two haemophagocytic histiocytic sarcomas (HaeHS) were confirmed. PDGFRβ was variably positive in most histiocytic cases, while KIT was negative in all. Clinical presentation, treatment and outcome were also evaluated. Partial responses were recorded in measurable disease with tyrosine kinase inhibitors and lomustine, and radiotherapy achieved long-term control in some cases. Survival times were shortest in HaeHS and disseminated disease. PDGFRβ, but not KIT, may represent a therapeutic target in feline histiocytic disorders but more studies are needed to investigate other potential treatment targets.
Collapse
Affiliation(s)
- E Treggiari
- Small Animal Teaching Hospital, School of Veterinary Science, University of Liverpool, Neston, UK
| | - L Ressel
- Section of Pathology, School of Veterinary Science, University of Liverpool, Neston, UK
| | - G A Polton
- North Downs Specialist Referrals, Bletchingley, UK
| | | | - I Desmas
- Royal Veterinary College, Queen Mother Hospital for Animals, Hatfield, UK
| | - L Blackwood
- Small Animal Teaching Hospital, School of Veterinary Science, University of Liverpool, Neston, UK
| |
Collapse
|
18
|
|
19
|
Farcas N, Arzi B, Verstraete FJM. Oral and maxillofacial osteosarcoma in dogs: a review. Vet Comp Oncol 2012; 12:169-80. [DOI: 10.1111/j.1476-5829.2012.00352.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2012] [Revised: 07/31/2012] [Accepted: 07/31/2012] [Indexed: 11/29/2022]
Affiliation(s)
- N. Farcas
- William R. Pritchard Veterinary Medical Teaching Hospital, School of Veterinary Medicine; University of California-Davis; Davis CA USA
| | - B. Arzi
- Department of Surgical and Radiological Sciences, School of Veterinary Medicine; University of California-Davis; Davis CA USA
| | - F. J. M. Verstraete
- Department of Surgical and Radiological Sciences, School of Veterinary Medicine; University of California-Davis; Davis CA USA
| |
Collapse
|
20
|
Demetriou JL, Brearley MJ, Constantino-Casas F, Addington C, Dobson J. Intentional marginal excision of canine limb soft tissue sarcomas followed by radiotherapy. J Small Anim Pract 2012; 53:174-81. [DOI: 10.1111/j.1748-5827.2011.01186.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
21
|
Mayer-Stankeová S, Fidel J, Wergin MC, Hauser B, Sumová A, Goitein G, Pedroni E, Lomax AJ, Schneider U, Blattmann H, Kaser-Hotz B. Proton spot scanning radiotherapy of spontaneous canine tumors. Vet Radiol Ultrasound 2009; 50:314-8. [PMID: 19507399 DOI: 10.1111/j.1740-8261.2009.01542.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Thirty dogs with spontaneous tumors were irradiated with proton therapy using a novel spot scanning technique to evaluate the safety and efficacy of the system, and to study the acute and late radiation reactions. Nasal tumors, soft tissue sarcomas, and miscellaneous tumors of the head were treated with a median total dose of 52.5 Gy given in 3.5 Gy fractions. Acute effects, late effects, tumor response, and outcome were analyzed. No unexpected radiation reactions were seen, however two dogs did develop in-field osteosarcoma, and one dog developed in-field bone necrosis. Complete response to therapy was seen in 40% (12/30), partial response in 47% (14/30), and no response in 13% (4/30). Median survival for all dogs was 385 days (range of 14-4583 days). Dogs with nasal cavity tumors had a median survival of 385 days (range of 131-1851 days) and dogs with soft tissue sarcomas had a median survival time of 612 days (range of 65-4588 days). Treatment outcome was similar to historical controls. This new proton spot scanning technique proved to be safe and reliable.
Collapse
|
22
|
Sustained high-level polyclonal hematopoietic marking and transgene expression 4 years after autologous transplantation of rhesus macaques with SIV lentiviral vector-transduced CD34+ cells. Blood 2009; 113:5434-43. [PMID: 19339698 DOI: 10.1182/blood-2008-10-185199] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
We previously reported that lentiviral vectors derived from the simian immunodeficiency virus (SIV) were efficient at transducing rhesus hematopoietic repopulating cells. To evaluate the persistence of vector-containing and -expressing cells long term, and the safety implications of SIV lentiviral vector-mediated gene transfer, we followed 3 rhesus macaques for more than 4 years after transplantation with transduced CD34+ cells. All 3 animals demonstrated significant vector marking and expression of the GFP transgene in T cells, B cells, and granulocytes, with mean GFP+ levels of 6.7% (range, 3.3%-13.0%), 7.4% (4.2%-13.4%), and 5.6% (3.1%-10.5%), respectively. There was no vector silencing in hematopoietic cells over time. Vector insertion site analysis of granulocytes demonstrated sustained highly polyclonal reconstitution, with no evidence for progression to oligoclonality. A significant number of clones were found to contribute at both 1-year and 3- or 4-year time points. No vector integrations were detected in the MDS1/EVI1 region, in contrast to our previous findings with a gamma-retroviral vector. These data show that lentiviral vectors can mediate stable and efficient long-term expression in the progeny of transduced hematopoietic stem cells, with an integration profile that may be safer than that of standard Moloney murine leukemia virus (MLV)-derived retroviral vectors.
Collapse
|